PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.
Zheng LiYaming LiXiaolong WangQifeng YangPublished in: Cancer cell international (2021)
Our results indicated that PPP2R2B could serve as a promising biomarker for TNBC, and help predict immunotherapeutic response and guide personalized strategies in TNBC treatment.
Keyphrases